Table 1. Patient characteristics.
| Patient sequence | Gender | Age (years) | ECOG PS | Histology (Lauren classification) | Prior therapy [no. lines] |
|---|---|---|---|---|---|
| 01 | M | 48 | 0 | Adenocarcinoma (intestinal) | mDCF [1] |
| 02 | F | 63 | 1 | Adenocarcinoma (diffuse) | EOX, mDCF [2] |
| 03 | F | 68 | 1 | Adenocarcinoma (diffuse) | mDCF, FOLFOX [2] |
| 04 | M | 63 | 1 | Adenocarcinoma (intestinal) | EOX, ELF [2] |
| 05 | M | 55 | 0 | Adenocarcinoma (intestinal) | mDCF [1] |
| 06 | F | 69 | 1 | Adenocarcinoma (intestinal) | mDCF, FOLFOX [2] |
| 07 | M | 66 | 0 | Adenocarcinoma (intestinal) | Paclitaxel/carboplatin/capecitabine [1] |
| 08 | F | 65 | 1 | Adenocarcinoma (intestinal) | EOX, FOLFIRI, docetaxel/cisplatin [3] |
| 09* | F | 73 | 0 | Adenocarcinoma (intestinal) | FOLFOX/trastuzumab, docetaxel/trastuzumab, irinotecan/trastuzumab [3] |
| 10 | F | 50 | 1 | Adenocarcinoma (diffuse) | mDCF, FOLFOX, FOLFIRI, paclitaxel/ramucirumab [4] |
*, only patient with tumor HER2 overexpression. mDCF, modified docetaxel/cisplatin/fluorouracil; EOX, epirubicin/oxaliplatin/capecitabine; FOLFOX, folinic acid/fluorouracil/oxaliplatin; ELF, etoposide/leucovorin/fluorouracil; FOLFIRI, folinic acid/fluorouracil/irinotecan; HER2, human epidermal growth factor receptor 2; ECOG PS, ECOG performance status; M, man; F, female.